Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study

Journal of the Neurological Sciences

Volumn 370, Issue , 2016, Pages 224-228

  Xu, Yan ^a   Wang, Qian ^a   Ren, Hai tao ^a   Qiao, Lin ^a   Zhang, Yao ^a   Fei, Yun Yun ^a   Zhao, Yan ^a   Cui, Li ying ^a,b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Azathioprine; Cyclophosphamide; Mycophenolate mofetil; Neuromyelitis optica spectrum disorder (NMOSD); Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; ADVERSE OUTCOME; AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OBSERVATIONAL STUDY; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; THROMBOCYTOPENIA; COMPARATIVE STUDY; KAPLAN MEIER METHOD; NEUROMYELITIS OPTICA; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MYCOPHENOLIC ACID; NEUROMYELITIS OPTICA; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84989878315     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.09.035     Document Type: Article

References (26)

1. [1] Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J., Weinshenker, B.G., The spectrum of neuromyelitis optica. Lancet Neurol. 6 (2007), 805–815.
2. [2] Wingerchuk, D.M., Banwell, B., Bennett, J.L., et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2015), 177–189.
3. [3] Wingerchuk, D.M., Hogancamp, W.F., O'Brien, P.C., Weinshenker, B.G., The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (1999), 1107–1114.
4. [4] Kim, W., Kim, S.H., Kim, H.J., New insights into neuromyelitis optica. J Clinical Neurol 7 (2011), 115–127.
5. [5] Mandler, R.N., AhmedW, D.J.E., Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 (1998), 1219–1220.
6. [6] Watanabe, S., Misu, T., Miyazawa, I., et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult. Scler. 13 (2007), 968–974.
7. [7] Jeong, I.H., Park, B., Kim, S.H., Hyun, J.W., Joo, J., Kim, H.J., Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult. Scler. 22 (2016), 329–339.
8. [8] Elsone, L., Kitley, J., Luppe, S., et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult. Scler. 20 (2014), 1533–1540.
9. [9] Mealy, M.A., Wingerchuk, D.M., Palace, J., Greenberg, B.M., Levy, M., Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71 (2014), 324–330.
10. [10] Torres, J., Pruitt, A., Balcer, L., Galetta, S., Markowitz, C., Dahodwala, N., Analysis of the treatment of neuromyelitis optica. J. Neurol. Sci. 351 (2015), 31–35.
11. [11] Costanzi, C., Matiello, M., Lucchinetti, C.F., et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77 (2011), 659–666.
12. [12] Bichuetti, D.B., Lobato de Oliveira, E.M., Oliveira, D.M., Amorin de Souza, N., Gabbai, A.A., Neuromyelitis optica treatment: analysis of 36 patients. Arch. Neurol. 67 (2010), 1131–1136.
13. [13] Qiu, W., Kermode, A.G., Li, R., et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J. Clin. Neurosci. 22 (2015), 1178–1182.
14. [14] Huh, S.Y., Kim, S.H., Hyun, J.W., et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 71 (2014), 1372–1378.
15. [15] Jacob, A., Matiello, M., Weinshenker, B.G., et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol. 66 (2009), 1128–1133.
16. [16] Yaguchi, H., Sakushima, K., Takahashi, I., et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern. Med. 52 (2013), 969–972.
17. [17] Bichuetti, D.B., Oliverira, E.M., Boulos Fde, C., Gabbai, A.A., Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch. Neurol. 69 (2012), 938–939.
18. [18] Ramanathan, R.S., Malhotra, K., Scott, T., Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 14 (2014), 51–55.
19. [19] Kitley, J., Elsone, L., George, J., et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J. Neurol. Neurosurg. Psychiatry 84 (2013), 918–921.
20. [20] Minagar, A., Sheremata, W.A., Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care 2 (2000), 43–49.
21. [21] Kim, S.H., Kim, W., Park, M.S., Sohn, E.H., Li, X.F., Kim, H.J., Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch. Neurol. 68 (2011), 473–479.
22. [22] Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63 (2006), 957–963.
23. [23] McLeod, H.L., Siva, C., The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics 3 (2002), 89–98.
24. [24] Barile-Fabris, L., Ariza-Andraca, R., Olguin-Ortega, L., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 64 (2005), 620–625.
25. [25] Rogers, S.J., Williams, C.S., Román, G.C., Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants. Drugs 64 (2004), 123–132.
26. [26] Sellner, J., Boggild, M., Clanet, M., et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol. 17 (2010), 1019–1032.